Hans E Seidel
Overview
Explore the profile of Hans E Seidel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dwyer S, Ruth J, Seidel H, Raz A, Chodosh L
Breast Cancer Res
. 2024 Oct;
26(1):143.
PMID: 39425240
Background: Mortality from breast cancer is principally due to tumor recurrence. Recurrent breast cancers arise from the pool of residual tumor cells, termed minimal residual disease, that survive treatment and...
2.
Ruth J, Pant D, Pan T, Seidel H, Baksh S, Keister B, et al.
Breast Cancer Res
. 2021 Jun;
23(1):63.
PMID: 34088357
Background: Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades. While clinical latency has been postulated to...
3.
Oran A, Adams C, Zhang X, Gennaro V, Pfeiffer H, Mellert H, et al.
Oncotarget
. 2016 Sep;
7(45):72395-72414.
PMID: 27590350
Despite ubiquitous activation in human cancer, essential downstream effector pathways of the MYC transcription factor have been difficult to define and target. Using a structure/function-based approach, we identified the mitochondrial...
4.
Zhang X, Pfeiffer H, Mellert H, Stanek T, Sussman R, Kumari A, et al.
Mol Cell Biol
. 2011 Oct;
31(24):5037-45.
PMID: 21986497
Aberrant MYC expression is a common oncogenic event in human cancer. Paradoxically, MYC can either drive cell cycle progression or induce apoptosis. The latent ability of MYC to induce apoptosis...